FLXN Flexion Therapeutics Inc.

19.53
+0.54  (+3%)
Previous Close 18.99
Open 19.11
Price To Book 102.79
Market Cap 745,553,063
Shares 38,174,760
Volume 1,448,766
Short Ratio
Av. Daily Volume 611,360
Stock charts supplied by TradingView

NewsSee all news

  1. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150

  2. Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings

    Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scalesIn this analysis of concordant pain reporters,

  3. Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights

    Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2Full-year 2019 ZILRETTA net sales guidance range tightened to

  4. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500

  5. Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019

    BURLINGTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial discontinued - noted November 7, 2019.
Zilretta
Osteoarthritis of the hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
PDUFA date for sNDA filing delayed. Decision due in the coming weeks - noted November 11, 2019.
Zilretta - FX006 repeat
Osteoarthritis of the knee
Phase 2 trial to be completed 1H 2021.
Zilretta - FX006
Shoulder osteoarthritis (OA) and frozen shoulder
Phase 1 trial to commence 4Q 2019 with initial data due in 2021.
FX201
Osteoarthritis (OA)

Latest News

  1. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150

  2. Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings

    Post-hoc sensitivity analysis assessed efficacy in patients who reported moderate-to-severe osteoarthritis (OA) pain prior to treatment on both ADP and WOMAC-A scalesIn this analysis of concordant pain reporters,

  3. Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights

    Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $21.8 million in Q3 representing 29% growth over Q2Full-year 2019 ZILRETTA net sales guidance range tightened to

  4. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to four new employees consisting of an aggregate of 14,700 stock options and 2,500

  5. Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019

    BURLINGTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its third-quarter 2019 financial results after the close of the U.S. financial markets

  6. Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis

    In addressing a highly prevalent, non-monogenic musculoskeletal disease, FX201 has the potential to open a new treatment avenue for gene therapy  A single intra-articular injection of FX201 has the potential to both

  7. Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

    BURLINGTON, Mass., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has informed the company it needs additional time to

  8. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 80,550 stock options and 13,425

  9. Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis (OA)

    BURLINGTON, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics (NASDAQ:FLXN) is teaming up with Chris Dickerson, a former New York Yankees outfielder and member of the 2011 and 2012 playoff teams, to raise

  10. Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

    BURLINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual Cell

  11. Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.

    Interactive memorial developed by the National Safety Council pays tribute to more than 22,000 victims of the opioid crisis and offers resources to help stem the epidemicExhibit will be on display Sept. 23-28 at the

  12. Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

    Flexion's new locally delivered product candidate, FX301, will combine Xenon's NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogelFX301 is a potential first-in-class therapy with the aim of providing pain

  13. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced equity inducement grants to nine new employees consisting of an aggregate of 25,900 stock options and 4,350

  14. Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference

    BURLINGTON, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led